The Lymphocyte Phenotype in Patients with Primary Fibromyalgia

References

• Bengtsson A., Ernerudh J., Vrethem M., Skogh T. Absence of autoantibodies in primary fibromyalgia. J Rheumatol 1990; 17: 1682–1683
   PubMed Web of Science ®Google Scholar
• Bennett R. M., Clark S. R., Campbell S. M., Burckhardt C. S. Low levels of somatomedin C in patients with the fibromyalgia syndrome. Arthritis Rheum 1992; 35: 1113–1116
   PubMed Web of Science ®Google Scholar
• Berg P. A., Klein R. Fibromyalgie-Syndrom. Eine neuroendokrinolo-gische Autoimmunerkrankung?. Dtsch med Wschr 1994; 119: 429–435
   PubMed Web of Science ®Google Scholar
• Calco C. F., Chavanel G., Senik A. Substance P enhances 11–2 expression in activated human T cells. J Immunol 1992; 148: 3498–3504
   PubMed Web of Science ®Google Scholar
• Caro X. Immunofluorescent detectionof IgG at dermal-epidermal junction in patients with apparent primary fibrositis syndrome. Arthritis Rheum 1984; 27: 1174–1178
   PubMed Web of Science ®Google Scholar
• Cleveland C. H., Fisher R. H., Brestel E. P., Esinhart J. D., Metzger W. J. Chronic rhinitis: an underrecognized association with fibromyalgia. Allergy Proc 1992; 13: 263–267
   PubMedGoogle Scholar
• Crofford L. J. Neuroendocrine aspects of fibromyalgia. J of Musculoskeletal Pain 1994; 3: 125–133
   Google Scholar
• Eide P. K., Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain Res 1991; 564: 33–39
   Google Scholar
• Elam M., Johansson G., Wallin B. G. Do patients with primary fibromyalgia have an altered muscle sympathetic nerve activity?. Pain 1992; 48: 371–375
   PubMed Web of Science ®Google Scholar
• Ferraccioli G., Cavalieri F., Salaffi F., Fontana S., Scita F., Nolli M., Maestri D. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol 1990; 17: 869–873
   PubMed Web of Science ®Google Scholar
• Fischer A. A. Pressure threshold measurement of diagnosis of myofascial pain and evaluation of treatment results. Clin J Pain 1987; 2: 207–214
   Google Scholar
• Goldenberg D. L. Fibromyalgia syndrome: An emerging but controversial condition. JAMA 1987; 257: 2782–2787
   PubMed Web of Science ®Google Scholar
• Hader N., Rimon D., Kinarty A., Lahat N. Altered interleukin-2 secretion in patients with primary fibromyalgia syndrome. Arthritis Rheum 1991; 34: 866–872
   PubMed Web of Science ®Google Scholar
• Jessop D. S., Chowdrey H. S., Larsen P. J., Lightman S. L. Substance P: Multifunctional eptide in the hypothalamo-pituitary system?. J Endocrinol 1992; 132: 331–337
   PubMed Web of Science ®Google Scholar
• Klein R., Bänsch M., Berg P. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendo-crinology 1992; 17: 593–598
   PubMed Web of Science ®Google Scholar
• McCain G. A., Tilbe K. S. Diurnal hormone variation in fibromyalgia syndrome: A comparison with rheumatoid arthritis. J Rheumatol (suppl 19) 1989; 16: 154–157
   Google Scholar
• Meske-Brand S., Kapp A., Müller W. Die generalisierte Tendomyopathie, ein syndrom im rahmen der atopie?. Akt Rheumatol 1984; 9: 156–158
   Google Scholar
• Murphy R. M., Zemlan F. P. Differential effects of substance P on serotonin modulated spinal nociceptive reflexes. Psychopharmacology (Berlin) 1987; 93: 118–121
   PubMed Web of Science ®Google Scholar
• Peter J. B., Wallace D. J. Abnormal immune regulation in fibromyalgia. Arthritis Rheum 1988; 31: 24
   Google Scholar
• Rameshwar P., Gascon P., Ganea D. Immunoregulatory effects of neuropeptides. Stimulation of interleukin-2 production by substance P. J Neuroimmunol 1992; 37: 65–74
   PubMed Web of Science ®Google Scholar
• Russell I. J. Biochemical abnormalities in fibromyalgia syndrome. J Muskuloskeletal Pain 1994; 2: 101–115
   Google Scholar
• Russell I. J., Michalek J. E., Vipraio G. A., et al. Serum serotonin and platelet 3H-imipramine binding receptor density in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19: 104–109
   PubMed Web of Science ®Google Scholar
• Russell I. J., Michalek J. E., Vipraio G. A., Fletcher E. M., Wall K. Serum aminoacids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989; 19: 158–163
   Google Scholar
• Russell I. J., Orr M. D., Littman B., Vipraio G. A., Alboukrek D., Michalek J. E., Lopez Y., McKillip F. Elevated cerebrospinal fluid levels of substance P in patients with fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593–1601
   PubMed Web of Science ®Google Scholar
• Russell I. J., Vaeroy H., Javors M., Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 35: 550–556
   PubMed Web of Science ®Google Scholar
• Russell I. J., Vipraio G. A., Craig F. E., King D. E., Monteil M. M. False CD 19 positive-CD5 cells in fibromyalgia. Arthritis Rheum 1994; 37(suppl)350
   Google Scholar
• Russell I. J., Vipraio G. A., Lopez Y. M. Serum serotonin in fibromyalgia syndrome, rheumatoid arthritis, osteoarthritis and healthy normal controls. Arthritis Rheum 1993; 36: 223
   Google Scholar
• Russell I. J., Vipraio G. A., Tovar Z., Michalek J., Fletcher E. Abnormal natural killer cell activity in fibrositis syndrome in responsive in vitro to 11–2. Arthritis Rheum 1988; 31: 24
   Google Scholar
• Samborski W., Pawlik I., Konys J., Mackiewicz U. The assesments of atopia symptoms in fibromyalgia patients. Reumatologia 1994; 4: 45–52
   Google Scholar
• Samborski W., Stratz T., Kretzman W., Mennet P., Muller W. Vergleichende undersuchugen uber das vorkommen vegetativer und funktioneller beschwerden bei lumbalgien und generalisierten tendomyopathien (fibromyalgia). Z Rheumatol 1991; 50: 378–381
   PubMed Web of Science ®Google Scholar
• Samborski W., Stratz T., Kretzman W., Mennet P., Muller W. The comparison of incidence of vegetative and functional symptoms in patients with fibromyalgia and chronic low back pain syndrome. Scand J Rheumatol 1992; 94(suppl)16
   Google Scholar
• Stratz T., Samborski W., Hrycaj P., Pap T., Mackiewicz S., Mennet P., Müller W. Die serotoninkonzentration im serum bei patienten mit generalisierter tendomyopathie (fibromyalgie) und chronischer polyarthritis. Med Klin 1993; 88: 458–462
   PubMedGoogle Scholar
• Vaeroy H., Helle R., Forre O., Kass E., Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988; 32: 21–26
   PubMed Web of Science ®Google Scholar
• Wolfe F., Smythe H. A., Yunus M. B., et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990; 33: 160–172
   PubMed Web of Science ®Google Scholar
• Yunus M. B., Dailey J. C., Aldag J. C., et al. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 1992; 19: 90–94
   PubMed Web of Science ®Google Scholar